Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 4/20 | 0.96 |
| ▸ | GBA2 | Q9HCG7 | 14/20 | 0.56 |
| ▸ | GAA | P10253 | 5/20 | 0.56 |
| ▸ | GBA1 | P04062 | 4/20 | 0.56 |
| ▸ | UGCG | Q16739 | 3/20 | 0.56 |
| ▸ | SI | P14410 | 2/20 | 0.56 |
| ▸ | AGL | P35573 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19557574 | 1.00 | MGAM (0.96) | MGAMGBA2GAAGBA1UGCG | |
| SCHEMBL18730387 | 0.98 | MGAM (1.00) | MGAMGBA2GAAGBA1UGCG | |
| SCHEMBL15598933 | 0.98 | MGAM (1.00) | MGAMGBA2GAAGBA1UGCG | |
| SCHEMBL17181679 | 0.98 | MGAM (1.00) | MGAMGBA2GAAGBA1UGCG | |
| SCHEMBL15598936 | 0.98 | MGAM (1.00) | MGAMGBA2GAAGBA1UGCG | |
| SCHEMBL17181678 | 0.98 | MGAM (1.00) | MGAMGBA2GAAGBA1UGCG | |
| SCHEMBL1816410 | 0.92 | MGAM (0.81) | MGAMGBA2GAAGBA1UGCG | |
| SCHEMBL2439221 | 0.91 | MGAM (0.81) | MGAMGBA2GAAGBA1UGCG | |
| SCHEMBL19557577 | 0.91 | MGAM (0.81) | MGAMGBA2GAAGBA1UGCG | |
| SCHEMBL19557628 | 0.91 | MGAM (0.81) | MGAMGBA2GAAGBA1UGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809537-B2 | Glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2017-11-07 | — | — | US | disclosed |
| US-9809537-B2 | Glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2017-11-07 | — | — | US | disclosed |
| US-9809537-B2 | Glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2017-11-07 | — | — | US | disclosed |
| US-20150274656-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. | 2015-10-01 | — | — | US | disclosed |
| US-20150274656-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. | 2015-10-01 | — | — | US | disclosed |
| US-20150274656-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. | 2015-10-01 | — | — | US | disclosed |
| WO-2014032188-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2014-03-06 | — | — | WO | disclosed |
| US-5663342-A | GLUCOSIDASE INHIBITORS, ANTIVIRAL, ANTI-HIV | G. D. SEARLE & CO. (US) | 1997-09-02 | — | — | US | disclosed |
| US-5612480-A | GLUCOSIDASE INHIBITORS | G. D. SEARLE & CO. (US) | 1997-03-18 | — | — | US | disclosed |
| US-5595981-A | GLUCOSIDASE INHIBITOR, VIRICIDE, NOJIRIMYCIN DERIVATIVES | G.D. SEARLE & CO. (US) | 1997-01-21 | — | — | US | disclosed |
| US-5451679-A | GLUCOSIDASE INHIBITORS, VIRICIDES | G. D. SEARLE & CO. (US) | 1995-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274656-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | OGA, ENGASE, OGT | MGAM 40/4885GBA2 44/4885GAA 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.